{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:55:13Z","timestamp":1793228113517,"version":"4.5.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s41669-022-00361-3","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T03:40:42Z","timestamp":1661226042000},"page":"3-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting"],"prefix":"10.1007","volume":"7","author":[{"given":"Conor","family":"McCloskey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Toboso","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Manevy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"issue":"19","key":"361_CR1","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.3390\/ijerph16193762","volume":"16","author":"MD Ruiz-Fern\u00e1ndez","year":"2019","unstructured":"Ruiz-Fern\u00e1ndez MD, Hern\u00e1ndez-Padilla JM, Ortiz-Amo R, Fern\u00e1ndez-Sola C, Fern\u00e1ndez-Medina IM, Granero-Molina J. Predictor factors of perceived health in family caregivers of people diagnosed with mild or moderate Alzheimer\u2019s disease. Int J Environ Res Public Health. 2019;16(19):3762.","journal-title":"Int J Environ Res Public Health"},{"key":"361_CR2","unstructured":"Global Cancer Observatory. Estimated number of deaths in 2020, worldwide, females, all ages. 2021. https:\/\/gco.iarc.fr\/today\/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=2&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0. Accessed Dec 2021."},{"issue":"8","key":"361_CR3","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.3390\/cancers12082081","volume":"12","author":"A Patel","year":"2020","unstructured":"Patel A, Unni N, Peng Y. The changing paradigm for the treatment of HER2-positive breast cancer. Cancers (Basel). 2020;12(8):2081.","journal-title":"Cancers (Basel)."},{"issue":"Suppl 2","key":"361_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000055404","volume":"61","author":"S M\u00e9nard","year":"2001","unstructured":"M\u00e9nard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology. 2001;61(Suppl 2):67\u201372.","journal-title":"Oncology"},{"issue":"11","key":"361_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392.","journal-title":"N Engl J Med"},{"issue":"16","key":"361_CR6","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659\u201372.","journal-title":"N Engl J Med"},{"issue":"16","key":"361_CR7","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673\u201384.","journal-title":"N Engl J Med"},{"issue":"19","key":"361_CR8","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol. 2005;23(19):4265\u201374.","journal-title":"J Clin Oncol"},{"issue":"9712","key":"361_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet (London, England). 2010;375(9712):377\u201384.","journal-title":"Lancet (London, England)."},{"issue":"14","key":"361_CR10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273\u201383.","journal-title":"N Engl J Med"},{"key":"361_CR11","unstructured":"Roche Registration Ltd. Herceptin\u00ae (trastuzumab). Summary of Product Characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/herceptin-epar-product-information_en.pdf. Accessed 1 June 2022."},{"key":"361_CR12","unstructured":"Genentech Inc. HERCEPTIN\u00ae\u00a0(trastuzumab). Prescribing Information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103792s5345lbl.pdf. Accessed 1 June 2022."},{"key":"361_CR13","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae):\u00a0Breast Cancer. Version 1.2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed Dec 2021."},{"key":"361_CR14","unstructured":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (German Gynecological Oncology Group A. Guidelines of the AGO Breast Committee. 2022. https:\/\/www.ago-online.de\/en\/leitlinien-empfehlungen\/leitlinien-empfehlungen\/kommission-mamma. Accessed June 2022."},{"issue":"12","key":"361_CR15","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623\u201349.","journal-title":"Ann Oncol"},{"issue":"8","key":"361_CR16","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194\u2013220.","journal-title":"Ann Oncol"},{"key":"361_CR17","unstructured":"Roche Registration Ltd. PERJETA\u00ae (pertuzumab). Summary of Product Characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/perjeta-epar-product-information_en.pdf. Accessed 1 June 2022."},{"key":"361_CR18","unstructured":"Genentech Inc. PERJETA\u00ae (pertuzumab). Prescribing Information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125409s124lbl.pdf. Accessed 1 June 2022."},{"issue":"6","key":"361_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791\u2013800.","journal-title":"Lancet Oncol"},{"issue":"2","key":"361_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122\u201331.","journal-title":"N Engl J Med"},{"key":"361_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:519\u201330.","journal-title":"Lancet Oncol"},{"key":"361_CR22","unstructured":"Roche Registration Ltd. Kadcyla\u00ae (trastuzumab emtansine). Summary of Product Characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kadcyla-epar-product-information_en.pdf. Accessed June 2022."},{"key":"361_CR23","unstructured":"Genentech Inc. KADCYLA\u00ae (ado-trastuzumab emtansine). Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125427s108lbl.pdf. Accessed June 2022."},{"issue":"7","key":"361_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328.","journal-title":"N Engl J Med"},{"issue":"3","key":"361_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/cam4.573","volume":"5","author":"E De Cock","year":"2016","unstructured":"De Cock E, Pivot X, Hauser N, Verma S, Kritikou P, Millar D, et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 2016;5(3):389\u201397.","journal-title":"Cancer Med"},{"issue":"2","key":"361_CR26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.breast.2015.01.002","volume":"24","author":"L Fallowfield","year":"2015","unstructured":"Fallowfield L, Osborne S, Langridge C, Monson K, Kilkerr J, Jenkins V. Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study. Breast. 2015;24(2):166\u201370.","journal-title":"Breast"},{"issue":"4","key":"361_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1055\/s-0034-1368173","volume":"74","author":"C Jackisch","year":"2014","unstructured":"Jackisch C, M\u00fcller V, Maintz C, Hell S, Ataseven B. Subcutaneous administration of monoclonal antibodies in oncology. Geburtshilfe Frauenheilkd. 2014;74(4):343\u20139.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"29","key":"361_CR28","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1200\/JCO.2009.22.6126","volume":"27","author":"SP Shivakumar","year":"2009","unstructured":"Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol. 2009;27(29):4858\u201364.","journal-title":"J Clin Oncol"},{"key":"361_CR29","unstructured":"De Cock E, Semiglazov V, Lopez-Vivanco G, Verma S, Pivot X, Gligorov J, et al. Time savings with trastuzumab subcutaneous vs. intravenous administration: a time and motion study. In: Poster presentation at the 13th St Gallen International Breast Cancer Conference; 13\u201316 March 2013. Abstract XXX; St Gallen."},{"key":"361_CR30","unstructured":"Genentech Inc. Herceptin Hylecta\u2122 (trastuzumab and hyaluronidase-oysk). Prescribing Information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761106s000lbl.pdf. Accessed Dec 2021."},{"issue":"9","key":"361_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","volume":"13","author":"G Ismael","year":"2012","unstructured":"Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre randomised trial. Lancet Oncol. 2012;13(9):869\u201378.","journal-title":"Lancet Oncol"},{"issue":"2","key":"361_CR32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/annonc\/mdu524","volume":"26","author":"C Jackisch","year":"2015","unstructured":"Jackisch C, Kim SB, Semiglazov V, Melichar B, Pivot X, Hillenbach C, et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol. 2015;26(2):320\u20135.","journal-title":"Ann Oncol"},{"key":"361_CR33","doi-asserted-by":"crossref","unstructured":"Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC, et al. Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years\u2019 treatment-free follow-up: final analysis from the phase III, open-label, randomized HannaH study. Cancer Res. 2017;78(4 Suppl):Abstract PD3-11 (and associated poster presentation).","DOI":"10.1158\/1538-7445.SABCS17-PD3-11"},{"issue":"5","key":"361_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0339","volume":"5","author":"C Jackisch","year":"2019","unstructured":"Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen S-C, et al. Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: Final analysis of the HannaH phase 3 randomized clinical trial. JAMA Oncol. 2019;5(5): e190339.","journal-title":"JAMA Oncol"},{"issue":"2","key":"361_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10549-021-06145-3","volume":"187","author":"S K\u00fcmmel","year":"2021","unstructured":"K\u00fcmmel S, Tondini CA, Abraham J, Nowecki Z, Itrych B, Hitre E, et al. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. Breast Can Res Treat. 2021;187(2):467\u201376.","journal-title":"Breast Can Res Treat."},{"issue":"2","key":"361_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109\u201319.","journal-title":"N Engl J Med"},{"issue":"6","key":"361_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","volume":"14","author":"SM Swain","year":"2013","unstructured":"Swain SM, Kim S-B, Cort\u00e9s J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461\u201371.","journal-title":"Lancet Oncol"},{"issue":"8","key":"361_CR38","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724\u201334.","journal-title":"N Engl J Med"},{"issue":"10","key":"361_CR39","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","volume":"14","author":"X Pivot","year":"2013","unstructured":"Pivot X, Gligorov J, M\u00fcller V, Barrett-Lee P, Verma S, Knoop A, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14(10):962\u201370.","journal-title":"Lancet Oncol"},{"issue":"10","key":"361_CR40","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/annonc\/mdu364","volume":"25","author":"X Pivot","year":"2014","unstructured":"Pivot X, Gligorov J, M\u00fcller V, Curigliano G, Knoop A, Verma S, et al. Patients\u2019 preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014;25(10):1979\u201387.","journal-title":"Ann Oncol"},{"key":"361_CR41","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejca.2017.05.009","volume":"82","author":"X Pivot","year":"2017","unstructured":"Pivot X, Spano JP, Espie M, Cottu P, Jouannaud C, Pottier V, et al. Patients\u2019 preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: results of the randomised MetaspHer study. Eur J Cancer. 2017;82:230\u20136.","journal-title":"Eur J Cancer"},{"key":"361_CR42","unstructured":"Genentech Inc. PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf). Prescribing Information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761170s000lbl.pdf. Accessed 1 June 2022."},{"key":"361_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ejca.2021.03.047","volume":"152","author":"J O'Shaughnessy","year":"2021","unstructured":"O\u2019Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, et al. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study. Eur J Cancer. 2021;152:223\u201332.","journal-title":"Eur J Cancer"},{"key":"361_CR44","unstructured":"Higgins J, Thomas J. Cochrane handbook for systematic reviews of interventions. Version 6.2. 2021. https:\/\/training.cochrane.org\/handbook\/current. Accessed Dec 2021."},{"issue":"7052","key":"361_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"MF Drummond","year":"1996","unstructured":"Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275\u201383.","journal-title":"BMJ"},{"key":"361_CR46","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the exonomic evaluation of health care programmes","author":"MF Drummond","year":"2005","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O\u2019Brien BJ, Stoddart GL. Methods for the exonomic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.","edition":"3"},{"issue":"5","key":"361_CR47","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/j.1524-4733.2008.00327.x","volume":"11","author":"L Molinier","year":"2008","unstructured":"Molinier L, Bauvin E, Combescure C, Castelli C, Rebillard X, Souli\u00e9 M, et al. Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health. 2008;11(5):878\u201385.","journal-title":"Value Health."},{"key":"361_CR48","doi-asserted-by":"crossref","unstructured":"Andrade S, Santos A. Hospital resources consumption associated with trastuzumab treatment in breast cancer in Portugal. Value Health. 2013;16(7):Abstract PCN147.","DOI":"10.1016\/j.jval.2013.08.546"},{"key":"361_CR49","doi-asserted-by":"crossref","unstructured":"Blein C, bernard Marty C, Priou V, Borg MC, mouret-Reynier M, Lebozec G, et al. A multicentric evaluation of consumables and transports cost of breast cancer patient\u2019s treated by trastuzumab according to the administration form (IV versus SC). Value Health. 2018;21(Suppl 3):Abstract PCN95.","DOI":"10.1016\/j.jval.2018.09.177"},{"key":"361_CR50","doi-asserted-by":"crossref","unstructured":"De Cock E, Pan YI, Tao S, Baidin P. Time savings with transtuzumab subcutaneous (SC) injection verse trastuzumab intravenous (IV) infusion: A time and motion study in 3 Russian centers. Value Health. 2014;17(7):Abstract PCN221.","DOI":"10.1016\/j.jval.2014.08.2380"},{"issue":"46","key":"361_CR51","doi-asserted-by":"publisher","first-page":"81343","DOI":"10.18632\/oncotarget.18527","volume":"8","author":"A Farolfi","year":"2017","unstructured":"Farolfi A, Silimbani P, Gallegati D, Petracci E, Schirone A, Altini M, et al. Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients. Oncotarget. 2017;8(46):81343\u20139.","journal-title":"Oncotarget"},{"issue":"10","key":"361_CR52","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.bulcan.2018.07.014","volume":"105","author":"M Favier","year":"2018","unstructured":"Favier M, Le Goc-Sager F, Vincent-Cantini I, Launay V, Giroux EA, Lievremont K, et al. Medico-economic benefits of subcutaneous formulations of trastuzumab and rituximab in day hospitalisation (SCuBA Study). Bull Cancer. 2018;105(10):862\u201372.","journal-title":"Bull Cancer"},{"issue":"8","key":"361_CR53","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/CAD.0000000000000648","volume":"29","author":"MG Franken","year":"2018","unstructured":"Franken MG, Kanters TA, Coenen JL, de Jong P, Koene HR, Lugtenburg PJ, et al. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. Anticancer Drugs. 2018;29(8):791\u2013801.","journal-title":"Anticancer Drugs"},{"issue":"2","key":"361_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211783","volume":"14","author":"E Hedayati","year":"2019","unstructured":"Hedayati E, Fracheboud L, Srikant V, Greber D, Wallberg S, Linder SC. Economic benefits of subcutaneous trastuzumab administration: a single institutional study from Karolinska University Hospital in Sweden. PLoS ONE. 2019;14(2): e0211783.","journal-title":"PLoS ONE"},{"issue":"6","key":"361_CR55","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1055\/s-0035-1546172","volume":"75","author":"C Jackisch","year":"2015","unstructured":"Jackisch C, M\u00fcller V, Dall P, Neumeister R, Park-Simon TW, Ruf-D\u00f6rdelmann A, et al. Subcutaneous trastuzumab for HER2-positive breast cancer\u2014evidence and practical experience in 7 German centers. Geburtshilfe Frauenheilkd. 2015;75(6):566\u201373.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"361_CR56","doi-asserted-by":"crossref","unstructured":"Lee VW, Cheng F. Cost-minimization analysis of trastuzumab intravenous versus trastuzumab subcutaneous regimen for breast cancer management in Hong Kong. Value Health. 2018;21(Suppl 2):Abstract PCN57.","DOI":"10.1016\/j.jval.2018.07.124"},{"key":"361_CR57","doi-asserted-by":"crossref","unstructured":"Lewis P, Jones H, Skelley K, Simpson R, Beresford M. Switching to subcutaneous trastuzumab administration: quantifying the benefits. Clin Oncol. 2017;29(6):Abstract E101.","DOI":"10.1016\/j.clon.2017.01.026"},{"key":"361_CR58","doi-asserted-by":"crossref","unstructured":"L\u00f3pez MA, Samanes MS, Tena IP, Alonso EF, Turlan VC, Sanchez MC, et al. Switching from intravenous to subcutaneous formulation of TRASTUZUMAB: Costs and safety. Eur J Hosp Pharm. 2017;24(Suppl 1):Abstract CP-127.","DOI":"10.1136\/ejhpharm-2017-000640.126"},{"issue":"12","key":"361_CR59","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1007\/s12094-017-1684-4","volume":"19","author":"G Lopez-Vivanco","year":"2017","unstructured":"Lopez-Vivanco G, Salvador J, Diez R, L\u00f3pez D, De Salas-Cansado M, Navarro B, et al. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. Clin Transl Oncol. 2017;19(12):1454\u201361.","journal-title":"Clin Transl Oncol"},{"key":"361_CR60","doi-asserted-by":"crossref","unstructured":"Nestorovska A, Naumoska Z, Grozdanova A, Stoleski D, Ivanovska A, Risteski M, et al. Subcutaneous vs intravenous administration of trastuzumab in HER2+ breast cancer patients: a Macedonian cost-minimization analysis. Value Health. 2015;18(7):Abstract PCN188.","DOI":"10.1016\/j.jval.2015.09.1205"},{"key":"361_CR61","doi-asserted-by":"crossref","unstructured":"Nierenberger A, Gessier F, Forges F, Simoens X. Subcutaneous trastuzumab versus intravenous trastuzumab: an impact study. Eur J Hosp Pharm. 2017;24(Suppl 1):Abstract PP-034.","DOI":"10.1136\/ejhpharm-2017-000640.481"},{"key":"361_CR62","first-page":"423","volume":"7","author":"RT North","year":"2015","unstructured":"North RT, Harvey VJ, Cox LC, Ryan SN. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study. Clinicoecon Outcomes Res. 2015;7:423\u201330.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"3","key":"361_CR63","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1016\/j.clbc.2019.01.011","volume":"19","author":"GL O'Brien","year":"2019","unstructured":"O\u2019Brien GL, O\u2019Mahony C, Cooke K, Kinneally A, Sinnott SJ, Walshe V, et al. Cost minimization analysis of intravenous or subcutaneous trastuzumab treatment in patients with HER2-positive breast cancer in Ireland. Clin Breast Cancer. 2019;19(3):e440\u201351.","journal-title":"Clin Breast Cancer"},{"key":"361_CR64","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.breast.2016.07.008","volume":"29","author":"S Olofsson","year":"2016","unstructured":"Olofsson S, Norrlid H, Karlsson E, Wilking U, Ragnarson TG. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer\u2014an observational study prospectively recording resource utilization in a Swedish healthcare setting. Breast. 2016;29:140\u20136.","journal-title":"Breast"},{"issue":"5","key":"361_CR65","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2217\/cer-2017-0048","volume":"7","author":"J Olsen","year":"2018","unstructured":"Olsen J, Jensen KF, Olesen DS, Knoop A. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer. J Comp Eff Res. 2018;7(5):411\u20139.","journal-title":"J Comp Eff Res."},{"key":"361_CR66","first-page":"227","volume":"8","author":"C Ponzetti","year":"2016","unstructured":"Ponzetti C, Canciani M, Farina M, Era S, Walzer S. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin\u2019s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clinicoecon Outcomes Res. 2016;8:227\u201333.","journal-title":"Clinicoecon Outcomes Res."},{"key":"361_CR67","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejogrb.2017.12.006","volume":"221","author":"WAA Tjalma","year":"2018","unstructured":"Tjalma WAA, Van den Mooter T, Mertens T, Bastiaens V, Huizing MT, Papadimitriou K. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: a time, motion and cost assessment study in a lean operating day care oncology unit. Eur J Obstet Gynecol Reprod Biol. 2018;221:46\u201351.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"361_CR68","unstructured":"Vangheluwe E, Giraud J, Pingaud C. Medico-economic impacts of use of subcutaneous formulations of rituximab and trastuzumab in outpatient care units. Eur J Oncol Pharm. 2018;1(3S):Abstract 191."},{"key":"361_CR69","doi-asserted-by":"crossref","unstructured":"Coombes M, Yin L, Liu I, Shek N, Rusu F, Mukherjee S. Subcutaneous trastuzumab for the treatment of HER2+ breast cancer in Canada: a cost-minimization study. Cancer Res. 2020;80(4 Suppl):Abstract P6-13-02.","DOI":"10.1158\/1538-7445.SABCS19-P6-13-02"},{"key":"361_CR70","doi-asserted-by":"crossref","unstructured":"Ghosh W, Lim S, Wong A. Cost-minimisation analysis of subcutaneous versus intravenous trastuzumab for the treatment of early breast cancer and metastatic breast cancer in Singapore. Value Health. 2018;21:Abstract PCN55.","DOI":"10.1016\/j.jval.2018.07.122"},{"issue":"2","key":"361_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227961","volume":"15","author":"L Rojas","year":"2020","unstructured":"Rojas L, Mu\u00f1iz S, Medina L, Pe\u00f1a J, Acevedo F, Pinto MP, et al. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer. PLoS ONE. 2020;15(2): e0227961.","journal-title":"PLoS ONE"},{"key":"361_CR72","doi-asserted-by":"crossref","unstructured":"A N, Ali A, Al-Tweigeri T, Zekri J, Awad N, Safwat M, et al. Financial impact of introducing SC trastuzumab (Herceptin) versus currently used IV trastuzumab (Herceptin) on the budgets of different hospitals across Kingdom of Saudi Arabia (KSA). Value Health. 2017;20(9):Abstract PCN60.","DOI":"10.1016\/j.jval.2017.08.143"},{"key":"361_CR73","doi-asserted-by":"crossref","unstructured":"Kashiura D, Souza PV, Garrido SD, Nardi E, Alves M. Budget impact model of subcutaneous trastuzumab compared with intravenous trastuzumab on the treatment of HER-2 positive breast cancer in the brazilian private healthcare system. Value Health. 2018;21(Suppl 3):Abstract PCN75.","DOI":"10.1016\/j.jval.2018.09.157"},{"key":"361_CR74","doi-asserted-by":"crossref","unstructured":"Poquet-Jornet JE, Carrera Hueso J, Crespo C, Cuesta-Grueso C, Ram\u00f3n Barrios MA, Gasent-Blesa JM, et al. Budget impact analysis with use of subcutaneus trastuzumab. Value Health. 2018;21(Suppl 3):Abstract PCN80.","DOI":"10.1016\/j.jval.2018.09.162"},{"key":"361_CR75","doi-asserted-by":"crossref","unstructured":"Calvache J, Briceno V. Budget impact analysis of the use of trastuzumab SC in the treatment of HER2 positive in public health institutions of Ecuador. Value Health. 2017;20.","DOI":"10.1016\/j.jval.2017.08.2970"},{"key":"361_CR76","doi-asserted-by":"crossref","unstructured":"Agirrezabal I, Gaikwad I, Cirillo L, Lothgren M. Predicted treatment costs and savings per patient of Kanjinti\u00ae (trastuzumab biosimilar) vs. subcutaneous (SC) and intravenous (IV) Herceptin\u00ae and other trastuzumab biosimilars in italy. Value Health. 2018;21(Suppl 3):Abstract PCN103.","DOI":"10.1016\/j.jval.2018.09.186"},{"key":"361_CR77","doi-asserted-by":"crossref","unstructured":"D'Arpino A, Savoia M, Cirillo L, Despi\u00e9gel N, Haffemayer B, Giannopoulou A, et al. Comparative cost analysis of subcutaneous trastuzumab originator (Herceptin\u00ae) vs intravenous trastuzumab biosimilar (Kanjinti) from a hospital perspective in Italy. Value Health. 2019;22(Suppl 3):Abstract PCN72.","DOI":"10.1016\/j.jval.2019.09.269"},{"key":"361_CR78","doi-asserted-by":"crossref","unstructured":"Jang Y, Byrne A, Toron F, Yoon S. Budget impact analysis of intravenous biosimilars compared with intravenous originators and subcutaneous products. Value Health. 2018;21(Suppl 3):Abstract PMU26.","DOI":"10.1016\/j.jval.2018.09.1862"},{"key":"361_CR79","doi-asserted-by":"crossref","unstructured":"Todorovic V, Durutovic I, Ivanovska A, Zajmovic A. Subcutaneous vs intravenous administration of trastuzumab in HER2+ breast cancer patients: a montenegrin cost-minimization analysis. Value Health. 2017;20(9):Abstract PCN172.","DOI":"10.1016\/j.jval.2017.08.255"},{"key":"361_CR80","doi-asserted-by":"crossref","unstructured":"Villarreal-Garza C, O-Maldonado CDl, D\u00edaz-P\u00e9rez H, Mesa-Chavez F, Garc\u00eda-Garc\u00eda M, Cardona-Huerta S, et al. Cost and time savings of subcutaneous trastuzumab (SC-T) in a public health system in Mexico. J Clin Oncol. 2019;37(15 Suppl):Abstract e18387.","DOI":"10.1200\/JCO.2019.37.15_suppl.e18387"},{"issue":"3","key":"361_CR81","first-page":"213","volume":"19","author":"ZI De La Vega","year":"2017","unstructured":"De La Vega ZI, Celia A, Manuel P, Agust\u00edn S, Miguel C. Economic impact of the introduction of subcutaneous trastuzumab in the pharmacotherapeutic guide. Eur J Clin Pharm. 2017;19(3):213\u20135.","journal-title":"Eur J Clin Pharm"},{"key":"361_CR82","unstructured":"Lazaro Cebas A, Cortijo Cascajares S, Pablos Bravo S, Del Puy Goyache Goni M, Gonzalez Monterrubio G, Perez Cardenas MD, et al. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use. J BUON. 2017;22(2):334-9."},{"key":"361_CR83","doi-asserted-by":"crossref","unstructured":"Kulikov A, Rybchenko Y. Pharmacoeconomic evaluation of the use of trastuzumab for subcutaneous administration compared to intravenous dosage form in the treatment of breast cancer. Value Health. 2015;18(7):Abstract PCN189.","DOI":"10.1016\/j.jval.2015.09.1206"},{"key":"361_CR84","doi-asserted-by":"crossref","unstructured":"Martin C, Alcedo J, Ara\u00faz E. Comparative analysis of costs between subcutaneous formulation of trastuzumab versus intravenous formulation from the perspective of the Instituto Oncol\u00f3gico Nacional of Panam\u00e1 from January to December 2016. Cancer Res. 2018;78(4 Suppl):Abstract P4-12-3.","DOI":"10.1158\/1538-7445.SABCS17-P4-12-13"},{"issue":"10","key":"361_CR85","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.12968\/bjon.2019.28.10.S15","volume":"28","author":"H Mitchell","year":"2019","unstructured":"Mitchell H, Morrissey D. Intravenous versus subcutaneous trastuzumab: an economic and patient perspective. Br J Nurs. 2019;28(10):S15\u201320.","journal-title":"Br J Nurs"},{"key":"361_CR86","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jcpo.2017.05.001","volume":"13","author":"C Mylonas","year":"2017","unstructured":"Mylonas C, Skroumpelos A, Fountzilas G, Maniadakis N. Cost minimization analysis of Herceptin subcutaneous versus herceptin intravenous treatment for patients with HER2+ breast cancer in Greece. J Cancer Policy. 2017;13:11\u20137.","journal-title":"J Cancer Policy"},{"issue":"7","key":"361_CR87","doi-asserted-by":"publisher","first-page":"A640","DOI":"10.1016\/j.jval.2014.08.2310","volume":"17","author":"C Mylonas","year":"2014","unstructured":"Mylonas C, Kourlaba G, Fountzilas G, Skroumpelos A, Maniadakis N. Cost-minimization analysis of trastuzumab intravenous versus trastuzumab subcutaneous for the treatment of patients with HER2+ early breast cancer and metastatic breast cancer in Greece. Value Health. 2014;17(7):A640\u20131.","journal-title":"Value Health."},{"issue":"6","key":"361_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157957","volume":"11","author":"E De Cock","year":"2016","unstructured":"De Cock E, Kritikou P, Sandoval M, Tao S, Wiesner C, Carella AM, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS ONE. 2016;11(6): e0157957.","journal-title":"PLoS ONE"},{"issue":"11","key":"361_CR89","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3324\/haematol.2017.173583","volume":"102","author":"P Lugtenburg","year":"2017","unstructured":"Lugtenburg P, Avivi I, Berenschot H, Ilhan O, Marolleau JP, Nagler A, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017;102(11):1913\u201322.","journal-title":"Haematologica"},{"issue":"6","key":"361_CR90","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.clinthera.2017.05.342","volume":"39","author":"J Mihajlovic","year":"2017","unstructured":"Mihajlovic J, Bax P, van Breugel E, Blommestein HM, Hoogendoorn M, Hospes W, et al. Microcosting study of rituximab subcutaneous injection versus intravenous infusion. Clin Ther. 2017;39(6):1221\u201332.","journal-title":"Clin Ther"},{"issue":"1","key":"361_CR91","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00277-017-3147-y","volume":"97","author":"E Fargier","year":"2018","unstructured":"Fargier E, Ranchon F, Huot L, Guerre P, Safar V, Dony A, et al. SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. Ann Hematol. 2018;97(1):123\u201331.","journal-title":"Ann Hematol"},{"issue":"7","key":"361_CR92","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3111\/13696998.2014.914033","volume":"17","author":"S Rule","year":"2014","unstructured":"Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014;17(7):459\u201368.","journal-title":"J Med Econ"},{"key":"361_CR93","doi-asserted-by":"crossref","unstructured":"Lakhal RB, Kacem K, Raoudha M, Jabeur D, Denguir MS, Bouattour H, et al. Cost-minimization and budget impact analysis of mabthera subcutaneous formulation in non-Hodgkin\u2019s lymphoma (NHL): a case study from Tunisia. HemaSphere. 2019;3:Abstract PB2294.","DOI":"10.1097\/01.HS9.0000567644.31502.1f"},{"key":"361_CR94","doi-asserted-by":"crossref","unstructured":"Chansung K, Chuncharunee S, Khuhapinant A, Bunworasate U, Norasetthada L, Prayongratana K. Preference of rituximab subcutaneous (R-SC) in Thai patients with diffused large b-cell lymphoma (DLBCL) and follicular lymphoma (FL): a Thai context. Value Health. 2018;21(Suppl 2):Abstract PCN67.","DOI":"10.1016\/j.jval.2018.07.135"},{"key":"361_CR95","doi-asserted-by":"crossref","unstructured":"Delgado S\u00e1nchez O, Guti\u00e9rrez A, do Pazo F, Gin\u00e9s J, Martorell C, Boyeras B, et al. Comparative cost analysis of intravenous and subcutaneous administration of rituximab in lymphoma patients. Clinicoecon Outcomes Res. 2019;11:695-701.","DOI":"10.2147\/CEOR.S212257"},{"key":"361_CR96","unstructured":"Di Rocco A, Scerbo G, Ansuinelli M, al e. Efficacy, safety and cost analysis of subcutaneous vs intravenous rituximab in patients with diffuse large b-cell lymphoma treated with RCHOP. Haematologica. 2017;102:108."},{"key":"361_CR97","doi-asserted-by":"crossref","unstructured":"Fisher MD, Wallick C, Miller PJ, Walker MS, Lash S, Dawson KL, et al. How time spent on rituximab infusion impacts patient satisfaction, stress, employment, and caregiver burden. Blood. 2017;130(Suppl 1):Abstract 5666.","DOI":"10.1016\/j.jval.2018.04.303"},{"key":"361_CR98","unstructured":"Irwin S, Rowntree C, Cosh H, Bloodworth C. Positive benefits of changing from intravenous rituximab administration to subcutaneous administration: a single centre experience. British Journal of Haematology. 2017;176:Abstract E1151."},{"key":"361_CR99","unstructured":"Lebas E, Guillotel R, Evrard J, Kugarajah R, Lassiaz C, Diakhate C. Time and money: the issues of setting up a rituximab biosimilar in hospital. Eur J Oncol Pharm. 2018;1:Abstract 197."},{"key":"361_CR100","doi-asserted-by":"crossref","unstructured":"McBride A, Balu S, Campbell K, MacDonald K, Abraham I. Economic modeling for the US of intravenous vs subcutaneous rituximab in non-Hodgkin\u2019s lymphoma treated with R-CHOP. Value Health. 2018;21(Suppl 3):Abstract PCN93.","DOI":"10.1016\/j.jval.2018.09.175"},{"key":"361_CR101","unstructured":"McBride A, Balu S, Campbell K, MacDonald K, Abraham I. Economic modeling for the U.S. of intravenous versus subcutaneous rituximab as single-agent maintenance therapy in follicular lymphoma. J Manag Care Spec Pharm. 2018;24(10A Suppl):Abstract C29."},{"key":"361_CR102","doi-asserted-by":"crossref","unstructured":"McBride A, Balu S, Campbell K, MacDonald K, Abraham I. Subcutaneous versus intravenous rituximab in non-Hodgkin lymphoma treated with R-CHOP: Economic modeling for the US. Blood. 2018;132(Suppl 1):Abstract 4776.","DOI":"10.1182\/blood-2018-99-113283"},{"key":"361_CR103","unstructured":"Nikolov O, Sterjev Z, Dimovski A, Kapedanovska-Nestorovska A, Naumovska Z, Grozdanova A, et al. Cost-minimization analysis of rituximab subcutaneous formulation versus intravenous administration of rituximab for the treatment of non-hodgkin\u2019s lymphoma in the Republic of Macedonia. Haematologica. 2017;102:Abstract E1471."},{"key":"361_CR104","unstructured":"Tomarchio V, Surano MA, Tafuri MA, Becilli M, Sarlo C, Berti P, et al. Management, economic and social impact of sub-cutaneous rituximab administration in lymphoproliferative malignancies. Haematologica. 2017;102(Suppl 1):Abstract P736."},{"issue":"1","key":"361_CR105","first-page":"1","volume":"5","author":"A Cicchetti","year":"2018","unstructured":"Cicchetti A, Coretti S, Mascia D, Mazzanti N, Refolo P, Rolli FR, et al. Assessing social and economic impact of subcutaneous mAbs in oncology. Glob Reg Health Technol Assess. 2018;5(1):1\u20139.","journal-title":"Glob Reg Health Technol Assess."},{"key":"361_CR106","doi-asserted-by":"crossref","unstructured":"Chansung K, Sirijerachai C, Teawtrakul N. Cost minimization study between intravenous rituximab (r-iv) vs subcutaneous rituximab (R-SC) in Thai patients with diffused large b-cell lymphoma (DLBCL): a simulation of electronic health record (E-HR) and evidence synthesis. Value Health. 2018;21(Suppl 2):Abstract PSY9.","DOI":"10.1016\/j.jval.2018.07.825"},{"key":"361_CR107","first-page":"111","volume":"102","author":"O Annibali","year":"2017","unstructured":"Annibali O, Tomarchio V, Becilli M. Management, economic and social impact of sub-cutaneous rituximab administration in diffuse large b cell lymphoma (DLBCL) and follicular lymphoma. Haematologica. 2017;102:111.","journal-title":"Haematologica"},{"key":"361_CR108","unstructured":"Gomes G, Ho R, Rufino C, Alves M. Budget impact analysis of rituximab IV versus SC from public Brazilian hospital. Value Health. 2017;20(5):Abstract PCN63."},{"key":"361_CR109","doi-asserted-by":"crossref","unstructured":"Kashiura D, Souza PV, Sa AB, Santos BR, Nardi E, Alves M. Budget impact model of subcutaneous rituximab compared with intravenous rituximab on the treatment of CD-20 positive non-Hodgkin lymphoma in the Brazilian private healthcare system. Value Health. 2018;21:Abstract PCN67.","DOI":"10.1016\/j.jval.2018.09.149"},{"key":"361_CR110","doi-asserted-by":"crossref","unstructured":"Rauf M, Dada R, Awad N, Safwat M, Narang A, Goyal R. To determine the financial imapct of introducing SC rituximab (MABTHERA) vs. currently used IV rituximab (MABTHERA) on the budgets of different hospitals across the Kingdom of Saudi Arabia (KSA). Value Health. 2017;20(9):Abstract PCN69.","DOI":"10.1016\/j.jval.2017.08.152"},{"issue":"5","key":"361_CR111","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3747\/co.25.4231","volume":"25","author":"DA Stewart","year":"2018","unstructured":"Stewart DA, Boudreault JS, Maturi B, Boras D, Foley R. Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites. Curr Oncol. 2018;25(5):300\u20136.","journal-title":"Curr Oncol"},{"issue":"8","key":"361_CR112","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/13696998.2017.1328423","volume":"20","author":"J Cristino","year":"2017","unstructured":"Cristino J, Finek J, Jandova P, Kolek M, P\u00e1sztor B, Giannopoulou C, et al. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic. J Med Econ. 2017;20(8):799\u2013812.","journal-title":"J Med Econ"},{"issue":"4","key":"361_CR113","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/CAD.0000000000000741","volume":"30","author":"S Li","year":"2019","unstructured":"Li S, Wu X, Chen P, Pei Y, Zheng K, Wang W, et al. Interferon-alpha versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial. Anticancer Drugs. 2019;30(4):402\u20139.","journal-title":"Anticancer Drugs"},{"issue":"5","key":"361_CR114","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13696998.2018.1445634","volume":"21","author":"N Raje","year":"2018","unstructured":"Raje N, Roodman GD, Willenbacher W, Shimizu K, Garc\u00eda-Sanz R, Terpos E, et al. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. J Med Econ. 2018;21(5):525\u201336.","journal-title":"J Med Econ"},{"issue":"4","key":"361_CR115","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3111\/13696998.2012.675380","volume":"15","author":"A Stopeck","year":"2012","unstructured":"Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, et al. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2012;15(4):712\u201323.","journal-title":"J Med Econ"},{"issue":"7","key":"361_CR116","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.clinthera.2018.05.012","volume":"40","author":"TT Zhang","year":"2018","unstructured":"Zhang TT, Wang S, Wan N, Zhang L, Zhang Z, Jiang J. Cost-effectiveness of daratumumab-based triplet therapies in patients with relapsed or refractory multiple myeloma. Clin Ther. 2018;40(7):1122\u201339.","journal-title":"Clin Ther"},{"issue":"9","key":"361_CR117","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1007\/s00520-017-3697-5","volume":"25","author":"JJ Body","year":"2017","unstructured":"Body JJ, Gatta F, De Cock E, Tao S, Kritikou P, Wimberger P, et al. An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: Results from three European countries. Support Care Cancer. 2017;25(9):2823\u201332.","journal-title":"Support Care Cancer"},{"issue":"10","key":"361_CR118","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.bulcan.2017.08.007","volume":"104","author":"F Despiau","year":"2017","unstructured":"Despiau F, Zagala Y, Delord JP, Montastruc M, Lacaze JL, Ferrand R, et al. Observational study of outpatient unit duration of stay depending on the route of administration (intravenous vs subcutaneous) for a targeted therapy. Bull Cancer. 2017;104(10):869\u201374.","journal-title":"Bull Cancer"},{"key":"361_CR119","doi-asserted-by":"crossref","unstructured":"Mateos MV, Nahi H, Legiec W. Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA. J Clin Oncol. 2019;37(15 Suppl):Abstract 8005.","DOI":"10.1200\/JCO.2019.37.15_suppl.8005"},{"issue":"2","key":"361_CR120","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/0091270012436560","volume":"53","author":"C Wynne","year":"2013","unstructured":"Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I\/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol. 2013;53(2):192\u2013201.","journal-title":"J Clin Pharmacol"},{"key":"361_CR121","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043828","volume":"10","author":"AG Lai","year":"2020","unstructured":"Lai AG, Pasea L, Banerjee A, Hall G, Denaxas S, Chang WH, et al. Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open. 2020;10: e043828.","journal-title":"BMJ Open"},{"key":"361_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103365","volume":"163","author":"M Tagliamento","year":"2021","unstructured":"Tagliamento M, Agostinetto E, Bruzzone M, Ceppi M, Saini KS, de Azambuja E, et al. Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;163: 103365.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"28","key":"361_CR123","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2217\/fon-2019-0368","volume":"15","author":"KC Anderson","year":"2019","unstructured":"Anderson KC, Landgren O, Arend RC, Chou J, Jacobs IA. Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. Future Oncol. 2019;15(28):3267\u201381.","journal-title":"Future Oncol"},{"issue":"5","key":"361_CR124","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40258-013-0045-x","volume":"11","author":"E Tetteh","year":"2013","unstructured":"Tetteh E, Morris S. Systematic review of drug administration costs and implications for biopharmaceutical manufacturing. Appl Health Econ Health Policy. 2013;11(5):445\u201356.","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"361_CR125","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","volume":"32","author":"B Bittner","year":"2018","unstructured":"Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425\u201340.","journal-title":"BioDrugs"},{"issue":"2","key":"361_CR126","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/14737167.2019.1554437","volume":"19","author":"A Inotai","year":"2019","unstructured":"Inotai A, Agh T, Karpenko AW, Zemplenyi A, Kalo Z. Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries. Expert Rev Pharmacoecon Outcomes Res. 2019;19(2):105\u201313.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"361_CR127","unstructured":"Roche Registration Ltd. Herceptin\u00ae (trastuzumab). Summary of Product Characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/herceptin-epar-product-information_en.pdf. Accessed Sept 2021."},{"key":"361_CR128","unstructured":"Genentech Inc. Herceptin\u00ae\u00a0(trastuzumab). Prescribing Information. 2021. https:\/\/www.gene.com\/download\/pdf\/herceptin_prescribing.pdf. Accessed Sept 2021."},{"key":"361_CR129","unstructured":"Roche Registration GmbH. PHESGO\u00ae (pertuzumab and trastuzumab). Summary of Product Characteristics. 2022. https:\/\/www.ema.europa.eu\/documents\/product-information\/phesgo-epar-product-information_en.pdf. Accessed 1 June 2022."},{"key":"361_CR130","doi-asserted-by":"crossref","unstructured":"Kolberg HK, Jackisch C, Hurvitz SA, Winstone J, Barham H, Hanes V, et al. Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review. Breast. 2021;57.","DOI":"10.1016\/j.breast.2021.03.003"},{"key":"361_CR131","unstructured":"Wright JM, Jones GB. Developing the subcutaneous drug delivery route. Med Res Archiv. 2017;5(12)."},{"issue":"28","key":"361_CR132","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2217\/fon-2019-0368","volume":"15","author":"KC Anderson","year":"2019","unstructured":"Anderson KC, Landgren O, Arend RC, Chou J, Jacobs IA. Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. Fut Oncol. 2019;15(28):3267\u201381.","journal-title":"Fut Oncol."},{"key":"361_CR133","doi-asserted-by":"crossref","unstructured":"Altini M, Gentili N, Balzi W, Musuraca G, Maltoni R, Masini C, et al. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology. Expert Rev Pharmacoeconomics Outcomes Res. 2020:1\u20137.","DOI":"10.1080\/14737167.2020.1764353"},{"issue":"1","key":"361_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100007","volume":"6","author":"A Wardley","year":"2021","unstructured":"Wardley A, Canon JL, Elsten L, Pena Murillo C, Badovinac Crnjevic T, Fredriksson J, et al. Flexible care in breast cancer. ESMO Open. 2021;6(1): 100007.","journal-title":"ESMO Open."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00361-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-022-00361-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00361-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T02:12:58Z","timestamp":1700964778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-022-00361-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":134,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1007\/s41669-022-00361-3","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"19 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was supported by F. Hoffmann-La Roche Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors received research funding support in the form of third-party medical writing support from F. Hoffmann-La Roche Ltd. CM is an employee of Clarivate, which was commissioned to perform this systematic review by F. Hoffmann-La Roche Ltd, and received travel expenses from F. Hoffmann-La Roche Ltd to attend a project scoping meeting. MTO and SN are employees of Clarivate, which was commissioned to perform this systematic review by F. Hoffmann-La Roche Ltd. MJG and FM are employees of and hold shares in F. Hoffmann-La Roche Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data supporting the findings of this study are available within the article or its supplementary materials.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in the concept and design of this systematic literature review (SLR). The protocol for this SLR was designed by CM, MTO, and SN, and was reviewed and approved by F. Hoffmann-La Roche Ltd. CM and MTO conducted the publication screening, data extraction, and quality assessments. SN was involved in quality control and offered strategic advice during all aspects of the project, including publication screening, data extraction, and quality assessments. CM and SN prepared the SLR report. All authors reviewed and critically revised the manuscript, approved the final version of the manuscript, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}